Next Investors logo grey

Dimerix has regulatory win in kidney disease fight


Published 19-APR-2016 16:34 P.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Dimerix (ASX:DXB) will be able to continue its phase II trial of flagship drug DMX-200 after it got the sign-off from the Therapeutic Goods Administration to do so.

It is currently undergoing phase II trials of the chronic kidney disease-fighting drug on two patients. The trials are almost complete.

DMX-200 combines two existing drugs, one which has anti-inflammatory properties and another one which is used to treat hypertension.

READ: DXB Chairman Dr James Williams talks to Finfeed

The latter doesn’t need sign-off, but the former does.

The TGA needs to approve the supply of the former, propagermanium, to patients on a case-by-case basis.

With approval in hand, the patients will now need clinician approval and to sign a participant agreement.

Pursuant to those, the patients will embark on a 24 week treatment period as part of the phase II trial.

DXB is currently on the lookout for up to 30 patients to test at four sites in Melbourne, with the aim of demonstrating that DMX-200 can safely reduce the level of proteinuria in the body.

Proteinuria is the presence of abnormal levels of protein in urine, which can be an indicator of chronic kidney disease in a patient.

Reducing proteinuria lowers the chances of CKD progression and its consequences such as the loss of renal function, and the development and progression of cardiovascular disease.

DMX chairman Dr James Williams said the approval would help in recruiting more patients in the trial, and was an endorsement of using the two drugs present in DMX-200 together.

“All trial participants are already on irbesartan thus continuing access to propagermanium indicates that the investigators involved do not have any safety concerns and consider there is potential benefit for patients to continue on the treatment,” he said.

“We believe this will support further recruitment into the trial.”

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.